<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">IJPN</journal-id><journal-title-group><journal-title>International Journal of Psychiatry and Neurology</journal-title></journal-title-group><issn pub-type="epub">2166-5788</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/IJPN.2021.102002</article-id><article-id pub-id-type="publisher-id">IJPN-42154</article-id><article-categories><subj-group subj-group-type="heading"><subject>IJPN20210200000_15254971.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  早期强化药物治疗对合并吞咽障碍大动脉粥样硬化性脑梗死的影响
  Effect of Early Intensive Drug Therapy on Atherosclerotic Cerebral Infarction with Dysphagia
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>作文</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>时双</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孙</surname><given-names>景环</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郑</surname><given-names>修广</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>重庆市江津区中医院，重庆</addr-line></aff><aff id="aff2"><addr-line>重庆市江津区中心医院神经内科，重庆</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>05</month><year>2021</year></pub-date><volume>10</volume><issue>02</issue><fpage>7</fpage><lpage>12</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：本研究探索早期(24小时内)启动经胃管强化药物治疗较延迟(第7天)治疗对合并吞咽障碍大动脉粥样硬化性急性脑梗死患者的影响。方法：选择2018年6月至2020年9月于神经内科确诊且住院治疗的合并吞咽障碍的大动脉粥样硬化性急性脑梗死患者84例，随机区组法1:1分为研究组和对照组。研究组24 h内安置胃管并启动强化药物治疗，对照组7天后开始置入胃管并强化药物治疗。主要终点事件为90天的良好功能(mRS评分为0，1，2，mRS评分范围为0~6，分数越高提示残疾程度越重)比例、神经功能改善程度(NIHSS评分下降程度)；次要功效指标：联合血管事件(症状性卒中，心肌梗死及血管源性死亡等)；主要安全目标为主要出血事件发生率，包括致命/危及生命的主要出血和其他主要出血。结果：90天mRS ≤ 2的比例，研究组50%，对照组为26.19%，差异有统计学意义(P = 0.042)；90天NIHSS评分降幅，研究组为6.57 &#177; 2.31，而对照组为4.45 &#177; 2.10，两组差异有统计学意义(P &lt; 0.01)。两组在联合血管事件及主要出血、不良事件等方面，无显著性差异。结论：24小时内安置胃管并强化药物治疗可以显著改善合并吞咽障碍的大动脉粥样硬化性脑梗死的功能预后，而不增加出血的风险。
   Objective: This study explored the effect of early (within 24 h) initiation of intensive medical thera-py via gastric tube on delayed (day 7) treatment in patients with acute cerebral infarction caused by large atherosclerosis with dysphagia. Methods: A total of 84 patients with atherosclerotic acute cerebral infarction complicated with dysphagia, who were diagnosed and hospitalized in the De-partment of Neurology from June 2018 to September 2020, were divided into study group and con-trol group by 1:1 used randomized block design. In the study group, gastric tube placement and in-tensive medical therapy were initiated within 24 h, and in the control group, gastric tube placement and intensive drug therapy were initiated 7 days later. The primary end points were the proportion of good function (a score of 0, 1, or 2 on the modified Rankin scale, which ranges from 0 to 6, with higher scores indicating more severe disability) at 90 days and the degree of improvement in neu-rological function (NIHSS score decreased). Secondary efficacy outcomes were combined vascular events (symptomatic stroke, myocardial infarction, or death from ischemic vascular causes). The primary safety outcomes were the incidence of major bleeding events, including fa-tal/life-threatening major bleeding and other major bleeding. Results: The proportion of 90 days mRS ≤ 2 was 50% in the study group and 26.19% in the control group, the difference was statisti-cally significant (P = 0.042). NIHSS score decreased by 6.57 &#177; 2.31 in the study group and 4.45 &#177; 2.10 in the control group at 90 days, and the difference between the two groups was statistically significant (P &lt; 0.01). There was no significant difference in vascular events, major bleeding and adverse events between the two groups. Conclusions: Gastric tube placement within 24 hours and intensive medication may significantly improve the functional outcome of large atherosclerotic cerebral infarction with dysphagia, without increasing the risk of bleeding.
 
</p></abstract><kwd-group><kwd>脑梗死，吞咽障碍，动脉粥样硬化，强化药物治疗, Cerebral Infarction</kwd><kwd> Dysphagia</kwd><kwd> Atherosclerotic</kwd><kwd> Intensive Medical Therapy</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：本研究探索早期(24小时内)启动经胃管强化药物治疗较延迟(第7天)治疗对合并吞咽障碍大动脉粥样硬化性急性脑梗死患者的影响。方法：选择2018年6月至2020年9月于神经内科确诊且住院治疗的合并吞咽障碍的大动脉粥样硬化性急性脑梗死患者84例，随机区组法1:1分为研究组和对照组。研究组24 h内安置胃管并启动强化药物治疗，对照组7天后开始置入胃管并强化药物治疗。主要终点事件为90天的良好功能(mRS评分为0，1，2，mRS评分范围为0~6，分数越高提示残疾程度越重)比例、神经功能改善程度(NIHSS评分下降程度)；次要功效指标：联合血管事件(症状性卒中，心肌梗死及血管源性死亡等)；主要安全目标为主要出血事件发生率，包括致命/危及生命的主要出血和其他主要出血。结果：90天mRS ≤ 2的比例，研究组50%，对照组为26.19%，差异有统计学意义(P = 0.042)；90天NIHSS评分降幅，研究组为6.57 &#177; 2.31，而对照组为4.45 &#177; 2.10，两组差异有统计学意义(P &lt; 0.01)。两组在联合血管事件及主要出血、不良事件等方面，无显著性差异。结论：24小时内安置胃管并强化药物治疗可以显著改善合并吞咽障碍的大动脉粥样硬化性脑梗死的功能预后，而不增加出血的风险。</p></sec><sec id="s2"><title>关键词</title><p>脑梗死，吞咽障碍，动脉粥样硬化，强化药物治疗</p></sec><sec id="s3"><title>Effect of Early Intensive Drug Therapy on Atherosclerotic Cerebral Infarction with Dysphagia<sup> </sup></title><p>Zuowen Zhang<sup>1</sup>, Shishuang Li<sup>1</sup>, Jinghuan Sun<sup>2</sup>, Xiuguang Zheng<sup>1*</sup></p><p><sup>1</sup>Department of Neurology, Jiangjin Central Hospital of Chongqing, Chongqing</p><p><sup>2</sup>Jiangjin TCM Hospital of Chongqing, Chongqing</p><p><img src="//html.hanspub.org/file/1-2240135x5_hanspub.png" /></p><p>Received: Mar. 23<sup>rd</sup>, 2021; accepted: Apr. 23<sup>rd</sup>, 2021; published: May 7<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/1-2240135x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: This study explored the effect of early (within 24 h) initiation of intensive medical therapy via gastric tube on delayed (day 7) treatment in patients with acute cerebral infarction caused by large atherosclerosis with dysphagia. Methods: A total of 84 patients with atherosclerotic acute cerebral infarction complicated with dysphagia, who were diagnosed and hospitalized in the Department of Neurology from June 2018 to September 2020, were divided into study group and control group by 1:1 used randomized block design. In the study group, gastric tube placement and intensive medical therapy were initiated within 24 h, and in the control group, gastric tube placement and intensive drug therapy were initiated 7 days later. The primary end points were the proportion of good function (a score of 0, 1, or 2 on the modified Rankin scale, which ranges from 0 to 6, with higher scores indicating more severe disability) at 90 days and the degree of improvement in neurological function (NIHSS score decreased). Secondary efficacy outcomes were combined vascular events (symptomatic stroke, myocardial infarction, or death from ischemic vascular causes). The primary safety outcomes were the incidence of major bleeding events, including fatal/life-threatening major bleeding and other major bleeding. Results: The proportion of 90 days mRS ≤ 2 was 50% in the study group and 26.19% in the control group, the difference was statistically significant (P = 0.042). NIHSS score decreased by 6.57 &#177; 2.31 in the study group and 4.45 &#177; 2.10 in the control group at 90 days, and the difference between the two groups was statistically significant (P &lt; 0.01). There was no significant difference in vascular events, major bleeding and adverse events between the two groups. Conclusions: Gastric tube placement within 24 hours and intensive medication may significantly improve the functional outcome of large atherosclerotic cerebral infarction with dysphagia, without increasing the risk of bleeding.</p><p>Keywords:Cerebral Infarction, Dysphagia, Atherosclerotic, Intensive Medical Therapy</p><disp-formula id="hanspub.42154-formula1"><graphic xlink:href="//html.hanspub.org/file/1-2240135x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/1-2240135x8_hanspub.png" /> <img src="//html.hanspub.org/file/1-2240135x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>目前，卒中已成为我国国民的第一位死亡原因 [<xref ref-type="bibr" rid="hanspub.42154-ref1">1</xref>]。在新发患者中，缺血性卒中占总体的70% [<xref ref-type="bibr" rid="hanspub.42154-ref2">2</xref>]，中国国家卒中登记(CNSR)数据显示 [<xref ref-type="bibr" rid="hanspub.42154-ref3">3</xref>]：大动脉粥样硬化性卒中约占所有缺血性卒中的45%。对于合并吞咽障碍的大动脉粥样硬化性急性缺血性脑卒中(acute ischemic stroke，AIS)的二级预防启动时间，目前指南未明确提示，也鲜有针对性研究。本研究旨在探索合并吞咽障碍的大动脉粥样硬化性AIS的早期管理，为临床决策提供依据。</p></sec><sec id="s6"><title>2. 研究资料</title><sec id="s6_1"><title>2.1. 一般资料</title><p>选取2018年6月至2020年9月于三甲医院神经内科确诊且住院治疗的合并吞咽障碍的TOAST分型为大动脉粥样硬化性急性脑梗死患者84例，研究组42例，对照组42例。两组基本情况见表1。两组患者在年龄、性别、合并脑血管病危险因素(高血压病、糖尿病、冠心病、吸烟、饮酒)等方面无差异。基线NIHSS评分研究组为12.29 &#177; 4.04，对照组为11.69 &#177; 4.13，两组中位数均为11分，两组无统计学差异。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Characteristics of the patients at baselin</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >基本情况</th><th align="center" valign="middle" >研究组(N = 42)</th><th align="center" valign="middle" >对照组(N = 42)</th></tr></thead><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >69.26 &#177; 7.43</td><td align="center" valign="middle" >68.02 &#177; 7.98<sup>*</sup></td></tr><tr><td align="center" valign="middle" >性别(男%)</td><td align="center" valign="middle" >29 (69. 05)</td><td align="center" valign="middle" >25 (59.52)<sup>*</sup></td></tr><tr><td align="center" valign="middle" >高血压病(%)</td><td align="center" valign="middle" >26 (61.90)</td><td align="center" valign="middle" >28 (66.67)<sup>*</sup></td></tr><tr><td align="center" valign="middle" >糖尿病(%)</td><td align="center" valign="middle" >14 (33.33)</td><td align="center" valign="middle" >16 (38.10)<sup>*</sup></td></tr><tr><td align="center" valign="middle" >冠心病(%)</td><td align="center" valign="middle" >11 (26.20)</td><td align="center" valign="middle" >9 (21.43)<sup>*</sup></td></tr><tr><td align="center" valign="middle" >吸烟(%)</td><td align="center" valign="middle" >19 (45.24)</td><td align="center" valign="middle" >17 (40.48)<sup>*</sup></td></tr><tr><td align="center" valign="middle" >饮酒(%)</td><td align="center" valign="middle" >16 (38.10)</td><td align="center" valign="middle" >19 (45.24)<sup>*</sup></td></tr><tr><td align="center" valign="middle" >基线NIHSS</td><td align="center" valign="middle" >12.29 &#177; 4.04</td><td align="center" valign="middle" >11.69 &#177; 4.13<sup>*</sup></td></tr></tbody></table></table-wrap><p>表1. 入组患者基线特征</p><p><sup>*</sup>两组间比较，P &gt; 0.05。</p></sec><sec id="s6_2"><title>2.2. 纳入标准和排出标准</title><p>入组标准：年龄 &gt; 18岁；急性脑梗死(起病24小时内)；经CTA/MRA/颈动脉超声证实存在责任血管大动脉狭窄 ≥ 50%，大动脉包括：主动脉弓、颈总动脉、颈内动脉、大脑中动脉M1段、椎动脉、基底动脉等；吞咽功能异常(洼田饮水试验3级或伴有意识障碍)；LDL-C在70~160 mg/dl之间。</p><p>排除标准：起病后已行静脉溶栓或桥接治疗；心源性卒中及其他病因卒中；预期寿命 &lt; 1年者；不能耐受他汀类药物治疗者；不能耐受抗血小板治疗者；血肌酐 &gt; 2.0 mg/dl或终末期肾病；严重肝功异常(AST/ALT &gt; 3倍正常上限)；近3月发生卒中者；置胃管禁忌者。</p><p>洼田饮水试验功能分级：叮嘱患者在不呛咳的情况下喝30 ml温水，根据喉头运动测定口咽含水至吞咽完的时间，测试2次，取最短时间。5秒钟内一次性顺利咽下，无呛咳为1级；5~10秒钟内无呛咳分2次以上咽下为2级；有呛咳能一次性咽下为3级；有呛咳2次以上咽下为4级；频繁呛咳难以全部咽下为5级。以 ≥ 3级为异常。洼田饮水试验由经过培训的康复技师评定。</p></sec><sec id="s6_3"><title>2.3. 研究方法</title><p>研究方案经医院伦理委员会通过，所有入组患者均需获得知情同意。使用随机区组设计，随机数表产生随机数，依据入院时间先后顺序，将患者1:1分为研究组和对照组。</p><p>药物干预方法：研究组第一天起安置胃管，自发病前24小时内经胃管服用药物(阿托伐他汀40 mg，30天后改为20 mg；阿司匹林首剂300 mg，次日起100 mg或阿司匹林首剂300 mg，次日起100 mg + 氯吡格雷首剂300 mg，次日起75 mg，根据是否合并颅内动脉重度狭窄选择双抗/单抗，双联抗血小板治疗为90天)；对照组自第7天起安置胃管，并经胃管服用药物同前。</p><p>应急预案：研究过程中出现脑出血、新发脑梗死、心肌梗死等，均按相应救治流程处理。</p></sec><sec id="s6_4"><title>2.4. 评定内容</title><p>主要功效指标：发病90天的良好功能(改良Rankin量表 [<xref ref-type="bibr" rid="hanspub.42154-ref4">4</xref>] (mRS)评分评估神经功能障碍康复程度，将mRS评分 ≤ 2分定义为预后良好，mRS评分 &gt; 2分定义为预后不良事件)比例、神经功能改善程度(美国国立卫生研究院卒中量表 [<xref ref-type="bibr" rid="hanspub.42154-ref5">5</xref>] (NIHSS)评分以及NIHSS下降程度)。次要功效指标：联合血管事件(症状性卒中，心肌梗死及血管源性死亡等)。主要安全指标：主要出血事件发生率、发病90天不良事件/严重不良事件等。</p></sec><sec id="s6_5"><title>2.5. 统计学方法</title><p>使用SPSS 22.0软件进行数据分析，计量资料以 x &#175; &#177; s 表示，组间比较采用成组t检验；计数资料采用例和百分比表示，组间比较采用χ<sup>2</sup>检验。P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><p>84例患者均完成90天的随访。两组均无死亡病例，预后较差病例，mRS评分5分者对照组4例，而研究组无(见图1)。主要功效指标：90天mRS ≤ 2的患者例数，研究组为21 (50%)，对照组为11 (26.19%)，两组差异有统计学意义。90天NIHSS评分降幅，研究组为6.57 &#177; 2.31，而对照组为4.45 &#177; 2.10，两组差异有统计学意义。两组在联合血管时间及主要出血、不良事件等方面，无显著性差异。次要功效指标方面，研究组有1例新发脑梗死，对照组则发生1例脑梗死、1例心肌梗死，两组统计无显著性差异。安全性指标方面，研究组发生1例消化道出血，对照组无出血事件，两组无统计学差异(见表2)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Efficacy and safety outcome</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >结果</th><th align="center" valign="middle" >研究组(N = 42)</th><th align="center" valign="middle" >对照组(N = 42)</th><th align="center" valign="middle" >P Value</th></tr></thead><tr><td align="center" valign="middle" >主要功效指标 90天mRS [<xref ref-type="bibr" rid="hanspub.42154-ref4">4</xref>] ≤ 2 (%)</td><td align="center" valign="middle" >21 (50.00)</td><td align="center" valign="middle" >11 (26.19)</td><td align="center" valign="middle" >0.042</td></tr><tr><td align="center" valign="middle" >90天NIHSS [<xref ref-type="bibr" rid="hanspub.42154-ref5">5</xref>] 降幅</td><td align="center" valign="middle" >6.57 &#177; 2.31</td><td align="center" valign="middle" >4.45 &#177; 2.10</td><td align="center" valign="middle" >&lt;0.01</td></tr><tr><td align="center" valign="middle" >次要功效指标 联合血管事件(%)</td><td align="center" valign="middle" >1 (3.38)<sup>#</sup></td><td align="center" valign="middle" >2 (4.76)<sup>##</sup></td><td align="center" valign="middle" >1.00</td></tr><tr><td align="center" valign="middle" >主要安全指标 主要出血、不良事件(%)</td><td align="center" valign="middle" >1 (3.38)<sup>*</sup></td><td align="center" valign="middle" >0 (0)</td><td align="center" valign="middle" >1.00</td></tr></tbody></table></table-wrap><p>表2. 功效与安全结果</p><p><sup>#</sup>脑梗死；<sup>##</sup>1例心肌梗死，1例脑梗死；<sup>*</sup>消化道出血。</p><p>图1. 90天MRS评分分布情况 [<xref ref-type="bibr" rid="hanspub.42154-ref4">4</xref>]</p><p>0分：无任何临床症状表现；1分：有症状且无明显残疾，但不会影响到工作及日常生活；2分：轻度残疾，影响工作，但是具备日常生活能；3分：有中度残疾，可自主行走，但是不具备日常生活自理能力；4分：中、重度残疾，不能自主行走，需他人协助日常生活；5分：重残，完全卧床，大小便失禁，需要他人进行照料；6分：死亡。</p></sec><sec id="s8"><title>4. 讨论</title><p>国内一项研究收集浙江省慢病监测信息管理系统中首次卒中患者78,189例，通过随访获得患者生存状况及死因。结果显示，患者当天即因卒中死亡占7.83％，卒中发生后其生存率迅速降低，之后生存曲线的降低速度逐渐减缓 [<xref ref-type="bibr" rid="hanspub.42154-ref6">6</xref>]，提示急性脑梗死救治的重心在其发病的早期。研究发现，院内死亡率的下降归因于住院期间规范的治疗策略，包括抗血小板药物、他汀类药物及卒中单元等 [<xref ref-type="bibr" rid="hanspub.42154-ref7">7</xref>]。对于非心源性卒中尤其是大动脉粥样硬化性AIS的二级预防治疗主要体现在抗血小板聚集和他汀类药物上。</p><p>抗血小板聚集方面，阿司匹林应用于急性卒中早期治疗(48小时内)已得到确认 [<xref ref-type="bibr" rid="hanspub.42154-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.42154-ref9">9</xref>]。有研究 [<xref ref-type="bibr" rid="hanspub.42154-ref10">10</xref>] 对43,041例急性脑卒中患者的抗血小板治疗结果进行了系统回顾，结果表明，在48小时内开始使用阿司匹林(每天160~300 mg)可降低早期复发中风的风险，并改善长期预后(无早期出血并发症的主要风险)。CHANCE研究 [<xref ref-type="bibr" rid="hanspub.42154-ref11">11</xref>] 发现阿司匹林联合氯吡格雷较单用阿司匹林更好地降低中国非致残性脑卒中或高危患者90天任何脑卒中的风险。根据CHANCE研究卒中存活曲线，药物作用最佳疗效时间为入组后一周左右，尤其是前2天。</p><p>他汀类药物在急性缺血性脑卒中二级预防中的地位得到肯定，2018 AHA/ASA急性缺血性脑卒中患者早期治疗指南 [<xref ref-type="bibr" rid="hanspub.42154-ref12">12</xref>] 中：高强度的他汀治疗应该作为一线治疗开始或继续在 ≤ 75岁的女性和男性中进行，除非有禁忌(IA推荐)。一项回顾性观察研究发现，针对血管再通治疗、大动脉中度以上狭窄或闭塞的患者，早期(发病第一天)使用他汀治疗可获得更多良好预后、更少的功能恶化 [<xref ref-type="bibr" rid="hanspub.42154-ref13">13</xref>]。目前，比较早期他汀药物疗效的随机对照研究较少，虽然ASSORT研究 [<xref ref-type="bibr" rid="hanspub.42154-ref14">14</xref>] (急性缺血性卒中患者早期VS延迟他汀治疗的随机对照试验)显示24 h内启动他汀治疗对于90天mRS无差异，但亚组分析显示，对于大动脉粥样硬化性脑梗死，他汀有获益趋势。</p><p>研究表明，50%~67%的卒中患者有吞咽障碍，40%的患者发生误吸性肺炎 [<xref ref-type="bibr" rid="hanspub.42154-ref15">15</xref>]，误吸性肺炎的30天死亡率为21%~30% [<xref ref-type="bibr" rid="hanspub.42154-ref16">16</xref>]。对于脑梗死患者而言，吞咽障碍还存在一个较大的问题就是口服药的摄入受到限制，而抗血小板药和他汀类药物主要经口服。对于合并吞咽障碍的大动脉粥样硬化性AIS的二级预防时机，缺少循证证据。结合CHANCE研究 [<xref ref-type="bibr" rid="hanspub.42154-ref11">11</xref>] 及SAMMPRIS [<xref ref-type="bibr" rid="hanspub.42154-ref17">17</xref>] 研究的卒中存活曲线可以看出，强化药物治疗对在干预早期尤其前48小时获益较明显。本研究，我们发现早期(24小时内)经胃管实施强化药物(抗血小板 + 他汀)可以显著降低合并吞咽障碍的动脉粥样硬化性脑梗死患者NIHSS评分，显著提高良好预后的比例(50%:26.19%)，而没有增加出血等不良事件的风险。据此，对于合并吞咽障碍的动脉粥样硬化性脑梗死患者，在急性期除了静脉溶栓、血管内介入再通外，尽早安置胃管给予抗血小板药物(静脉溶栓需24小时后)及他汀药物可能获益。当然，本研究限于经费等原因，入组例数较少，可能存在偏倚，需要大样本的随机对照研究加以证实上述结论。本研究全部入组病例基线NIHSS评分中位数11分，结论尚不能推及到轻度或重度上述脑梗死患者。</p></sec><sec id="s9"><title>基金项目</title><p>重庆市科卫联合医学科研课题(2018MSXM039)。</p></sec><sec id="s10"><title>文章引用</title><p>张作文,李时双,孙景环,郑修广. 早期强化药物治疗对合并吞咽障碍大动脉粥样硬化性脑梗死的影响Effect of Early Intensive Drug Therapy on Atherosclerotic Cerebral Infarction with Dysphagia[J]. 国际神经精神科学杂志, 2021, 10(02): 7-12. https://doi.org/10.12677/IJPN.2021.102002</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.42154-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Wu, S.M., et al. (2019) Stroke in China: Advances and Challenges in Epidemiology, Prevention, and Management. The Lancet Neurology, 18, 394-405.</mixed-citation></ref><ref id="hanspub.42154-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会神经病学分会脑血管病学组缺血性脑卒中二级预防指南撰写组. 中国缺血性脑卒中和短暂性脑缺血发作二级预防指南2010 [J]. 中华神经科杂志, 2010, 43(2): 154-160.</mixed-citation></ref><ref id="hanspub.42154-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Xu, J., Liu, L., Wang, Y., et al. (2012) TOAST Subtypes: Its Influence upon Doctors’ Decisions of Antihypertensive Pre-scription at Discharge for Ischemic Stroke Patients. Patient Preference and Adherence, 6, 911-914.  
&lt;br&gt;https://doi.org/10.2147/PPA.S38565</mixed-citation></ref><ref id="hanspub.42154-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">van Swieten, J.C., Koudstaal, P.J., Visser, M.C., et al. (1988) Interob-server Agreement for the Assessment of Handicap in Stroke Patients. Stroke, 19, 604-607. &lt;br&gt;https://doi.org/10.1161/01.STR.19.5.604</mixed-citation></ref><ref id="hanspub.42154-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Hacke, W., Kaste, M., Fieschi, C., et al. (1995) Intravenous Throm-bolysis with Recombinant Tissue Plasminogen Activator for Acute Hemispheric Stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA, 274, 1017-1025.  
&lt;br&gt;https://doi.org/10.1001/jama.1995.03530130023023</mixed-citation></ref><ref id="hanspub.42154-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">武海滨, 龚巍巍, 潘劲, 等. 首次脑卒中患者生存率和死亡影响因素的研究[J]. 中华流行病学杂志, 2014, 35(7): 812-816.</mixed-citation></ref><ref id="hanspub.42154-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Minnerup, J., Wersching, H., Unrath, M., et al. (2015) Explaining the Decrease of In-Hospital Mortality from Ischemic Stroke. PLoS ONE, 10, e0131473. &lt;br&gt;https://doi.org/10.1371/journal.pone.0131473</mixed-citation></ref><ref id="hanspub.42154-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">International Stroke Trial Collaborative Group (1997) The In-ternational Stroke Trial (IST): A Randomised Trial of Aspirin, Subcutaneous Heparin, Both, or Neither among 19435 Pa-tients with Acute Ischaemic Stroke. The Lancet, 349, 1569-1581. &lt;br&gt;https://doi.org/10.1016/S0140-6736(97)04011-7</mixed-citation></ref><ref id="hanspub.42154-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">CAST (Chinese Acute Stroke Trial) Collaborative Group (1997) CAST: Randomized Placebo-Controlled Trial of Early Aspirin Use in 20,000 Patients with Acute Ischaemic Stroke. The Lancet, 349, 1641-1649.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(97)04010-5</mixed-citation></ref><ref id="hanspub.42154-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Sandercock, P.A., Counsell, C., Gubitz, G.J. and Tseng, M.C. (2008) Antiplatelet Therapy for Acute Ischaemic Stroke. Cochrane Database of Systematic Reviews, No. 3, CD000029. &lt;br&gt;https://doi.org/10.1002/14651858.CD000029.pub2</mixed-citation></ref><ref id="hanspub.42154-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Y., Wang, Y., Zhao, X., et al. (2013) Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack. The New England Journal of Medicine, 369, 11-19. &lt;br&gt;https://doi.org/10.1056/NEJMoa1215340</mixed-citation></ref><ref id="hanspub.42154-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Powers, W.J., Rabinstein, A.A., Ackerson, T., et al. (2018) 2018 Guidelines for the Early Management of Patients with Acute Ischemic Stroke: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke, 49, e46-e110. &lt;br&gt;https://doi.org/10.1161/STR.0000000000000163</mixed-citation></ref><ref id="hanspub.42154-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Kang, J., Kim, N., Park, T.H., et al. (2015) Early Statin Use in Ischemic Stroke Patients Treated with Recanalization Therapy: Retrospective Observational Study. BMC Neurology, 15, 122. &lt;br&gt;https://doi.org/10.1186/s12883-015-0367-4</mixed-citation></ref><ref id="hanspub.42154-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Yoshimura, S., Uchida, K., Daimon, T., et al. (2017) Ran-domized Controlled Trial of Early Versus Delayed Statin Therapy in Patients with Acute Ischemic Stroke: ASSORT Trial (Administration of Statin on Acute Ischemic Stroke Patient). Stroke, 48, 3057-3063. &lt;br&gt;https://doi.org/10.1161/STROKEAHA.117.017623</mixed-citation></ref><ref id="hanspub.42154-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Teismann, I.K., Suntrup, S., Warnecke, T., et al. (2011) Cortical Swallowing Processing in Early Sub-Acute Stroke. BMC Neurology, 11, Article No. 34. &lt;br&gt;https://doi.org/10.1186/1471-2377-11-34</mixed-citation></ref><ref id="hanspub.42154-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Wirth, R., Dziewas, R., Beck, A.M., et al. (2016) Oropharyngeal Dysphagia in Older Persons—From Pathophysiology to Adequate Intervention: A Review and Summary of an Interna-tional Expert Meeting. Clinical Interventions in Aging, 11, 189-208. &lt;br&gt;https://doi.org/10.2147/CIA.S97481</mixed-citation></ref><ref id="hanspub.42154-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Scott, J.L., Pride, G.L., Zaidat, O.O., et al. (2011) Stenting versus Aggressive Medical Therapy for Intracranial Arterial Steno-sis. The New England Journal of Medicine, 365, 993-1003. &lt;br&gt;https://doi.org/10.1056/NEJMc1111906</mixed-citation></ref></ref-list></back></article>